康柏西普联合雷珠单抗治疗糖尿病性黄斑病变患者的临床疗效及安全性
Clinical efficacy and safety of Kangbusipu combined with leazu monoclonal antibody in the treatment of diabetic macular degeneration
杨静 1陈曦2
作者信息
- 1. 象山县红十字台胞医院 眼科,浙江 宁波 315731
- 2. 宁波大学医学院附属医院眼科,浙江 宁波 315000
- 折叠
摘要
目的 分析康柏西普联合雷珠单抗治疗糖尿病性黄斑病变患者的临床疗效及安全性.方法 选取2014年9月～2015年9月象山县红十字台胞医院眼科收治的糖尿病性黄斑病变患者66 例,根据随机数字法分为康柏西普组和雷珠单抗组,各33 例.2组均实施常规治疗以及对症治疗,康柏西普组给予康柏西普眼用注射液0.05 mL 玻璃体注射,雷珠单抗组给予雷珠单抗注射液0.05 mL 玻璃体注射,手术前3 d 及术后7 d,2 组均给予左氧氟沙星滴眼液点眼,每天4 次,连用3 d.治疗结束后比较2 组临床疗效以及不良反应发生情况.结果 治疗后,雷珠单抗组临床总有效率为90.91％,低于康柏西普组的93.94％( P< 0.05),康柏西普组不良反应发生率为12.12％,略低于雷珠单抗组15.15％,差异无统计学意义.结论 康柏西普与雷珠单抗治疗糖尿病性黄斑病变的临床疗效显著,安全性较高.
Abstract
Objective To investigate the clinical efficacy and safety of conbercept and lucentis in the treatment of age-related macular degeneration.Methods A total of 66 patients with age-related macular degeneration from our hospital were chosen,the patients or family members signed an agreement,were randomly divided into experiment group and control group with 33 cases in each group.Patients in the control group were treated by lucentis injection therapy; patients in the experiment group were treated by conbercept injection,determined serological indexes and ophthalmic indexes before and after treatment,and the clinical efficacy wascompared,the patients were followed up,the adverse reactions were recorded.Results After treatment,the vision restoration effective rate of the control group 48％was lower than the experiment group 80％,with statistical significance(P<0.05); the adverse reactions rate of the experiment group(20％)compared with the control group(16％),was no difference.Conclusion Conbercept injection in the treatment of age-related macular degeneration can decrease peripheral blood VEGF and CRP contents,reduce the CMT and CNV levels,reduce intraocular pressure,improve vision.
关键词
糖尿病性黄斑病变/康柏西普/雷珠单抗/临床疗效/安全性Key words
diabetic macular degeneration/conbercept/lucentis/clinical efficacy/safety引用本文复制引用
出版年
2017
NETL
NSTL
维普
万方数据